<HashMap><database>biostudies-literature</database><scores/><additional><submitter>De Michieli L</submitter><funding>National Center for Advancing Translational Sciences</funding><funding>NCATS NIH HHS</funding><funding>Mayo Clinic CTSA</funding><funding>National Institutes of Health</funding><funding>NIH HHS</funding><pagination>1080-1089</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8083261</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>67(8)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Limited data exist on high-sensitivity cardiac troponin (hs-cTn) for risk-stratification in COVID-19.&lt;h4>Methods&lt;/h4>We conducted a multicenter, retrospective, observational, US-based study of COVID-19 patients undergoing hs-cTnT. Outcomes included short-term mortality (in-hospital and 30-days post-discharge) and a composite of major adverse events, including respiratory failure requiring mechanical ventilation, cardiac arrest, and shock within the index presentation and/or mortality during the index hospitalization or within 30-days post-discharge.&lt;h4>Results&lt;/h4>Among 367 COVID-19 patients undergoing hs-cTnT, myocardial injury was identified in 46%. They had a higher risk for mortality (20% vs 12%, P &lt; 0.0001; unadjusted HR 4.44, 95% CI 2.13-9.25, P &lt; 0.001) and major adverse events (35% vs. 11%, P &lt; 0.0001; unadjusted OR 4.29, 95% CI 2.50-7.40, P &lt; 0.0001). Myocardial injury was associated with major adverse events (adjusted OR 3.84, 95% CI 2.00-7.36, P &lt; 0.0001) but not mortality. Baseline (adjusted OR 1.003, 95% CI 1.00-1.007, P = 0.047) and maximum (adjusted OR 1.005, 95% CI 1.001-1.009, P = 0.0012) hs-cTnT were independent predictors of major adverse events. Most (95%) increases were due to myocardial injury, with 5% (n = 8) classified as type 1 or 2 myocardial infarction. A single hs-cTnT &lt;6 ng/L identified 26% of patients without mortality, with a 94.9% (95% CI 87.5-98.6) negative predictive value and 93.1% sensitivity (95% CI 83.3-98.1) for major adverse events in those presenting to the ED.&lt;h4>Conclusions&lt;/h4>Myocardial injury is frequent and prognostic in COVID-19. While most hs-cTnT increases are modest and due to myocardial injury, they have important prognostic implications. A single hs-cTnT &lt;6 ng/L at presentation may facilitate the identification of patients with a favorable prognosis.</pubmed_abstract><journal>Clinical chemistry</journal><pubmed_title>High-Sensitivity Cardiac Troponin T for the Detection of Myocardial Injury and Risk Stratification in COVID-19.</pubmed_title><pmcid>PMC8083261</pmcid><funding_grant_id>UL1TR002377</funding_grant_id><funding_grant_id>UL1 TR002377</funding_grant_id><pubmed_authors>Mehta RA</pubmed_authors><pubmed_authors>Knott JD</pubmed_authors><pubmed_authors>Jaffe AS</pubmed_authors><pubmed_authors>De Michieli L</pubmed_authors><pubmed_authors>Sandoval Y</pubmed_authors><pubmed_authors>Yang EH</pubmed_authors><pubmed_authors>Akula A</pubmed_authors><pubmed_authors>Gulati R</pubmed_authors><pubmed_authors>Singh G</pubmed_authors><pubmed_authors>Hodge DO</pubmed_authors><pubmed_authors>Ola O</pubmed_authors><pubmed_authors>Singh R</pubmed_authors><pubmed_authors>Gharacholou M</pubmed_authors><pubmed_authors>Dworak M</pubmed_authors></additional><is_claimable>false</is_claimable><name>High-Sensitivity Cardiac Troponin T for the Detection of Myocardial Injury and Risk Stratification in COVID-19.</name><description>&lt;h4>Background&lt;/h4>Limited data exist on high-sensitivity cardiac troponin (hs-cTn) for risk-stratification in COVID-19.&lt;h4>Methods&lt;/h4>We conducted a multicenter, retrospective, observational, US-based study of COVID-19 patients undergoing hs-cTnT. Outcomes included short-term mortality (in-hospital and 30-days post-discharge) and a composite of major adverse events, including respiratory failure requiring mechanical ventilation, cardiac arrest, and shock within the index presentation and/or mortality during the index hospitalization or within 30-days post-discharge.&lt;h4>Results&lt;/h4>Among 367 COVID-19 patients undergoing hs-cTnT, myocardial injury was identified in 46%. They had a higher risk for mortality (20% vs 12%, P &lt; 0.0001; unadjusted HR 4.44, 95% CI 2.13-9.25, P &lt; 0.001) and major adverse events (35% vs. 11%, P &lt; 0.0001; unadjusted OR 4.29, 95% CI 2.50-7.40, P &lt; 0.0001). Myocardial injury was associated with major adverse events (adjusted OR 3.84, 95% CI 2.00-7.36, P &lt; 0.0001) but not mortality. Baseline (adjusted OR 1.003, 95% CI 1.00-1.007, P = 0.047) and maximum (adjusted OR 1.005, 95% CI 1.001-1.009, P = 0.0012) hs-cTnT were independent predictors of major adverse events. Most (95%) increases were due to myocardial injury, with 5% (n = 8) classified as type 1 or 2 myocardial infarction. A single hs-cTnT &lt;6 ng/L identified 26% of patients without mortality, with a 94.9% (95% CI 87.5-98.6) negative predictive value and 93.1% sensitivity (95% CI 83.3-98.1) for major adverse events in those presenting to the ED.&lt;h4>Conclusions&lt;/h4>Myocardial injury is frequent and prognostic in COVID-19. While most hs-cTnT increases are modest and due to myocardial injury, they have important prognostic implications. A single hs-cTnT &lt;6 ng/L at presentation may facilitate the identification of patients with a favorable prognosis.</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 Aug</publication><modification>2025-04-29T11:30:23.415Z</modification><creation>2025-04-06T19:53:55.162Z</creation></dates><accession>S-EPMC8083261</accession><cross_references><pubmed>33860295</pubmed><doi>10.1093/clinchem/hvab062</doi></cross_references></HashMap>